Top-News
Pharmazeutika USA

Syndax Pharmaceuticals News

Aktie
WKN:  A2AFL6 ISIN:  US87164F1057 US-Symbol:  SNDX
18,60 €
+0,00 €
0,00%
20.05.24 08:19:22
Handeln Depot/Watchlist
Aktienanzahl *
69,64 Mio.
Marktkapitalisierung *
1,30 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 14.12.2023

Syndax Pharmaceuticals News

15.05.24 - PR Newswire
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors PR Newswire
09.05.24 - PR Newswire
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference PR Newswire
08.05.24 - PR Newswire
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update PR Newswire
03.05.24 - PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
01.05.24 - PR Newswire
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 PR Newswire
10.04.24 - PR Newswire
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum PR Newswire
08.04.24 - PR Newswire
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session PR Newswire
05.04.24 - PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
28.03.24 - PR Newswire
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia PR Newswire
26.03.24 - PR Newswire
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire
18.03.24 - PR Newswire
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer PR Newswire
01.03.24 - PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
27.02.24 - PR Newswire
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update PR Newswire
26.02.24 - PR Newswire
Syndax Announces Participation at Two Upcoming Investor Conferences
Syndax Announces Participation at Two Upcoming Investor Conferences PR Newswire
20.02.24 - PR Newswire
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024 PR Newswire
02.02.24 - PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
01.02.24 - PR Newswire
Syndax Announces Participation at Two Upcoming Investor Conferences
Syndax Announces Participation at Two Upcoming Investor Conferences PR Newswire
05.01.24 - PR Newswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
02.01.24 - PR Newswire
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
02.01.24 - PR Newswire
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
Syndax Highlights Recent Updates and Anticipated 2024 Milestones PR Newswire

Newssuche

Videos

17.05.24 +6,63%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »